A matrix dispersion based on phospholipid complex system: preparation, lymphatic transport, and pharmacokinetics

References

• Riis BJ. Biochemical markers of bone turnover. II: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;95(5A):17S–21S.
   PubMedGoogle Scholar
• Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 2006;28(2):151–173.
   PubMed Web of Science ®Google Scholar
• Elsheikh MA, Elnaggar Y Sr., Gohar EY, et al. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int J Nanomedicine. 2012;7:3787–3802.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Aditya N, Kathuria H, et al. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm. 2014;87(1):114–124.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Ziaei V, Minaiyan M, et al. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles. Pharm Dev Technol. 2018;24(2):133–144.
   PubMed Web of Science ®Google Scholar
• Trontelj J, Vovk T, Bogataj M, et al. HPLC analysis of raloxifene hydrochloride and its application to drug quality control studies. Pharmacol Res. 2005;52(4):334–339.
   PubMed Web of Science ®Google Scholar
• Ram KJ, Sanjay T, Brahmeshwar M. Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetic evaluation. AAPS PharmSciTech. 2011;12(2):650–657.
   PubMed Web of Science ®Google Scholar
• Teeter JS, Meyerhoff RD. Environmental fate and chemistry of raloxifene hydrochloride. Environ Toxicol Chem. 2010;21(4):729–736.
   Google Scholar
• Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000;57(18):1669–1675.
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos. 2002;30(6):694–700.
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos. 2011;39(5):864–873.
   PubMed Web of Science ®Google Scholar
• Thörn HA, Yasin M, Dickinson PA, et al. Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery. Xenobiotica. 2012;42(9):917–928.
   PubMed Web of Science ®Google Scholar
• Golmohammadzadeh S, Farhadian N, Biriaee A, et al. Preparation, characterization and in-vitro evaluation of microemulsion of raloxifene hydrochloride. Drug Dev Ind Pharm. 2017;43(10):1619–1625.
   PubMed Web of Science ®Google Scholar
• Lu R, Liu S, Wang Q, et al. Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug/HP-β-cyclodextrin inclusion complexes. Die Pharm. 2015;70(12):791–797.
   PubMed Web of Science ®Google Scholar
• Khan J, Alexander A, Ajazuddin A, et al. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J Control Release. 2013;168(1):50–60.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang L, Zhang L, et al. Studies on the curcumin phospholipid complex solidified with Soluplus(®). J Pharm Pharmacol. 2017;70(2):242–249.
   PubMed Web of Science ®Google Scholar
• Ali KA, Jahanzeb M, Noratiqah M, et al. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733–2744.
   PubMed Web of Science ®Google Scholar
• Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24(4):381–388.
   PubMed Web of Science ®Google Scholar
• Elsheikh MA, Elnaggar YSR, Hamdy DA, et al. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: optimization and pharmacokinetics. Int J Pharm. 2018;535(1–2):316–324.
   PubMed Web of Science ®Google Scholar
• Lind ML, Jacobsen J, Holm R, et al. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci. 2008;35(3):211–218.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yan C, Jin D, et al. Solid dispersion of berberine–phospholipid complex/TPGS 1000/SiO2: preparation, characterization and in vivo studies. Int J Pharm. 2014;465(1–2):306–316.
   PubMed Web of Science ®Google Scholar
• Fan J, Dai Y, Shen H, et al. Application of soluplus to improve the flowability and dissolution of baicalein phospholipid complex. Molecules. 2017;22(5):776.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Dong W, Ye J, et al. A novel matrix dispersion based on phospholipid complex for improving oral bioavailability of baicalein: preparation, in vitro and in vivo evaluations. Drug Deliv. 2017;24(1):720–728.
   PubMed Web of Science ®Google Scholar
• Chen Chen T, Yu SC, Hsu CM, et al. A water-based topical Chinese traditional medicine (Zicao) for wound healing developed using 2-hydroxypropyl-beta-cyclodextrin. Colloids Surf B Biointerfaces. 2018;165:67–73.
   PubMed Web of Science ®Google Scholar
• Nagarsenker MS, Meshram RN, Ramprakash G. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J Pharm Pharmacol. 2010;52(8):949–956.
   Google Scholar
• Nagarsenkar MS, Shenai H. Influence of hydroxypropyl β-cyclodextrin on solubility and dissolution profile of ketoprofen in its solid dispersions. Drug Dev Commun. 2008;22(9–10):987–992.
   Google Scholar
• Gao H, Wei Y, Xi L, et al. Evaluation of intestinal absorption and bioavailability of a bergenin–phospholipid complex solid dispersion in rats. AAPS PharmSciTech. 2018;19(4):1720–1729.
   PubMed Web of Science ®Google Scholar
• Yue PF, Yuan HL, Li XY, et al. Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex. Int J Pharm. 2010;387(1–2):139–146.
   PubMed Web of Science ®Google Scholar
• Gao F, Zhang Z, Bu H, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Controlled Release. 2011;149(2):168–174.
   PubMed Web of Science ®Google Scholar
• Yang X, Jiang Q, Du P, et al. Preparation and characterization of solidified oleanolic acid–phospholipid complex aiming to improve the dissolution of oleanolic acid. Asian J Pharm Sci. 2016;11(2):241–247.
   Web of Science ®Google Scholar
• Maiti K, Mukherjee K, Gantait A, et al. Curcumin–phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1–2):155–163.
   PubMed Web of Science ®Google Scholar
• Laura R. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether beta-cyclodextrin binary and ternary complexes. Chem Pharm Bull. 2003;51(8):914–922.
   PubMed Web of Science ®Google Scholar
• Wang H, Cui Y, Fu Q, et al. A phospholipid complex to improve the oral bioavailability of flavonoids. Drug Dev Ind Pharm. 2015;41(10):1–11.
   Web of Science ®Google Scholar
• Ahmad H, Arya A, Agrawal S, et al. Phospholipid complexation of NMITLI118RT+: way to a prudent therapeutic approach for beneficial outcomes in ischemic stroke in rats. Drug Deliv. 2016;23(9):3606–3618.
   PubMed Web of Science ®Google Scholar
• Jena SK, Singh C, Dora CP, et al. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. Int J Pharm. 2014;473(1–2):1–9.
   PubMedGoogle Scholar
• Dora CP, Kushwah V, Katiyar SS, et al. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int J Pharm. 2017;534(1–2):1–13.
   PubMedGoogle Scholar
• Dora CP, Kushwah V, Katiyar SS, et al. Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. Int J Pharm. 2017;530(1–2):113–127.
   PubMed Web of Science ®Google Scholar
• Du P, Jiang QK, Yang RJ, et al. Nanonization of andrographolide by a wet milling method: the effects of vitamin E TPGS and oral bioavailability enhancement. RSC Adv. 2016;6(103):101404–101414.
   Web of Science ®Google Scholar
• Yumei LU, Chen C, Yang F, et al. Determination of equilibrium solubility and apparent oil/water partition coefficient of raloxifene hydrochloride. J Guangdong Pharm Univ. 2014;30:269–273.
   Google Scholar
• Alexander A, Ajazuddin  , Patel RJ, et al. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release. 2016;241:110–124.
   PubMed Web of Science ®Google Scholar
• Jadhav P, Petkar B, Pore Y, et al. Physicochemical and molecular modeling studies of cefixime–l-arginine–cyclodextrin ternary inclusion compounds. Carbohydr Polym. 2013;98(2):1317–1325.
   PubMed Web of Science ®Google Scholar
• Takada K, Yoshimura H, Shibata N, et al. Effect of administration route on the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles. J Pharm Dyn. 1986;9(2):156–160.
   PubMedGoogle Scholar
• Athmouni K, Mkadmini Hammi K, El Feki A, et al. Development of catechin-phospholipid complex to enhance the bioavailability and modulatory potential against cadmium-induced oxidative stress in rats liver. Arch Physiol Biochem. 2018;126(1):82–88.
   PubMed Web of Science ®Google Scholar